CRISPR Therapeutics

📍 Boston, United States🗓 Founded 2013👥 444 employees💰 Last funded Oct 2017
Biotechnology Research🌐 crisprtx.com
Website LinkedIn
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Canada
1
Frequently asked questions
Who invested in CRISPR Therapeutics?
CRISPR Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did CRISPR Therapeutics last raise funding?
The most recent investment in CRISPR Therapeutics recorded on gritt.io was in October 2017.
When was CRISPR Therapeutics founded?
CRISPR Therapeutics was founded in 2013.
What industry is CRISPR Therapeutics in?
CRISPR Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is CRISPR Therapeutics based?
CRISPR Therapeutics is headquartered in Boston, United States.